Deal Watch: Auxilium Accepts Endo Buyout Rather Than Completing Purchase Of QLT Shell
Executive Summary
Actavis continues filling out its portfolio by acquiring Durata, but leaves room for other transformational deals. Impax moves strongly into generics and adds an FDA-licensed manufacturing site in buying three companies under the Tower Holdings umbrella.
You may also be interested in...
Keeping Track: US FDA Approvals For Ibsrela, Gvoke And Nucala; A BTD For Tepotinib
The latest drug development news and highlights from our US FDA Performance Tracker.
Impax Buyouts Add Plant, Portfolio And Pipeline
By acquiring three interrelated, privately held companies, Impax adds several branded and generic products, a substantial generic pipeline and an FDA-licensed manufacturing site in New Jersey.
Second Genome Scores A Deal With Janssen, A First In The Field Of Microbiome Therapeutics
Second Genome’s ulcerative colitis research alliance with Janssen Biotech is a first in the burgeoning microbiome therapeutics space, which may be transitioning from venture investment to commercial partnering. But is the deal an inflection point or a fluke?